Heterocyclic compounds, preparation methods and uses thereof
Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.
1. A crystalline form of a compound having the following formula:
wherein the crystalline form is Form I, Form II, Form III, or Form IV,
wherein crystalline Form I is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 6.9, 11.4, 11.5, 13.0, 14.8, 17.4, 17.8, 18.1, 19.4, and 22.8 degrees 2 theta, ±0.2°; Form II is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 8.1, 15.6, and 18.8 degrees 2 theta, ±0.2°; Form III is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 6.6, 8.3, 11.5, 19.1, 19.9, and 22.0 degrees 2 theta, ±0.2°; and Form IV is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 6.7, 8.6, 16.6, 18.9, and 19.2 degrees 2 theta, ±0.2°.
2. The crystalline form of claim 1 , which is crystalline Form I, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.9, 11.4, 11.5, 13.0, 14.8, 17.4, 17.8, 18.1, 19.4, and 22.8 degrees 2 theta, ±0.2°.
3. The crystalline form of claim 1 , which is crystalline Form II, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 8.1, 15.6, and 18.8 degrees 2 theta, ±0.2°.
4. The crystalline form of claim 1 , which is crystalline Form III, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.6, 8.3, 11.5, 19.1, 19.9, and 22.0 degrees 2 theta, ±0.2°.
5. The crystalline form of claim 1 , which is crystalline Form IV, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.7, 8.6, 16.6, 18.9, and 19.2 degrees 2 theta, ±0.2°.
6. The crystalline form of claim 1 , which is substantially pure.
7. A pharmaceutical composition comprising the crystalline form of claim 1 , and optionally a pharmaceutically acceptable excipient.
8. A pharmaceutical composition comprising the crystalline form of claim 5 , wherein the pharmaceutical composition is free or substantially free of the compound in a solid form other than Form IV.
9. A crystalline form of a compound having the following formula:
wherein the crystalline form is crystalline Form A, Form B, Form C, or Form D, wherein the crystalline Form A is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 6.2, 12.6, 14.8, and 19.9 degrees 2 theta, ±0.2°; Form B is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 6.2, 12.6, 14.8, 19.0, and 19.8 degrees 2 theta, ±0.2°; Form C is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 6.2, 12.5, and 19.9 degrees 2 theta, ±0.2°; and Form D is characterized by an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks: 5.6, 11.2, 16.9, and 22.6 degrees 2 theta, ±0.2°.
10. The crystalline form of claim 9 , which is crystalline Form A, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.2, 12.6, 14.8, and 19.9 degrees 2 theta, ±0.2°.
11. The crystalline form of claim 9 , which is crystalline Form B, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.2, 12.6, 14.8, 19.0, and 19.8 degrees 2 theta, ±0.2°.
12. The crystalline form of claim 9 , which is crystalline Form C, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.2, 12.5, and 19.9 degrees 2 theta, ±0.2°.
13. The crystalline form of claim 9 , which is crystalline Form D, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 5.6, 11.2, 16.9, and 22.6 degrees 2 theta, ±0.2°.
14. The crystalline form of claim 9 , which is substantially pure.
15. A pharmaceutical composition comprising the crystalline form of claim 9 , and optionally a pharmaceutically acceptable excipient.
16. The crystalline form of claim 9 , which is crystalline Form A, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.2, 12.6, 13.8, 14.8, 15.1, 18.0, 19.6 and 19.9 degrees 2 theta, ±0.2°.
17. The crystalline form of claim 9 , which is crystalline Form A, characterized by an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 5A .
18. The crystalline form of claim 9 , which is crystalline Form B, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.2, 12.6, 13.6, 14.5, 14.8, 17.8, 19.0, 19.8, 21.4, 26.3, 31.9 and 38.6 degrees 2 theta, ±0.2°.
19. The crystalline form of claim 9 , which is crystalline Form B, characterized by an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 6A .
20. The crystalline form of claim 9 , which is crystalline Form C, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 6.2, 6.8, 7.3, 12.5, 14.2, 14.7, 15.7, 16.3, 19.9, 21.2, 22.9 and 26.1 degrees 2 theta, ±0.2°.
21. The crystalline form of claim 9 , which is crystalline Form C, characterized by an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 7A .
22. The crystalline form of claim 9 , which is crystalline Form D, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 5.6, 11.2, 15.8, 16.1, 16.9, 21.4, 22.6 and 34.3 degrees 2 theta, ±0.2°.
23. The crystalline form of claim 9 , which is crystalline Form D, characterized by an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 8A .